Zomig-ZMT

• Anti-migraine Agents
• Vasoconstrictor Agents
• Anti-inflammatory Agents
• Selective Serotonin Agonists
• ATC:N02CC03

• Zomig
• Zomig-ZMT

• No information avaliable

C₁₆H₂₁N₃O₂

http://www.rxlist.com/cgi/generic2/zolmit.htm

Zomig-ZMT FDA

No information avaliable

287.357 g/mol

No information avaliable

No information avaliable

Solid

1.363

Spray; Tablet

For the acute treatment of adult migraine (with or without auras)

Zolmitriptan is a selective 5-hydroxytryptamine receptor subtype agonist indicated for the acute treatment of migraine attacks with or without aura in adults. Zolmitriptan is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine. Zolmitriptan is an agonist for a vascular 5-hydroxytryptamine receptor subtype (probably a member of the 5-HT_1D family) having only a weak affinity for 5-HT_1A, 5-HT_5A, and 5-HT₇ receptors and no significant affinity or pharmacological activity at 5-HT₂, 5-HT₃ or 5-HT₄ receptor subtypes or at alpha1-, alpha2-, or beta-adrenergic, dopamine1,; dopamine2; muscarinic, or benzodiazepine receptors. This action in humans correlates with the relief of migraine headache. In addition to causing vasoconstriction, experimental data from animal studies show that Zolmitriptan also activates 5-HT₁ receptors on peripheral terminals of the trigeminal nerve innervating cranial blood vessels, which may also contribute to the antimigrainous effect of Zolmitriptan in humans.

40%

No information avaliable

No information avaliable

Humans and other mammals